The rise of copyright’s blockbuster initially fueled a period of growth for the drug industry, but recent changes present a uncertain scenario for those considering a stake. Lower-cost alternatives are eating into profits, and ongoing patent challenges add further risk to the equation. While some companies may still benefit from complementary off